HWZ Forums

Login Register FAQ Mark Forums Read

IHH Healthcare *Official* (SGX: Q0F)

Like Tree1Likes
  • 1 Post By yyhwin
Reply
 
LinkBack Thread Tools
Old 28-11-2017, 09:16 AM   #1
Senior Member
 
Join Date: Sep 2017
Posts: 1,479
IHH Healthcare *Official* (SGX: Q0F)

IHH Healthcare *Official* (SGX: Q0F)
Creating a new thread since cannot find existing thread.
Jupiter2017 is offline   Reply With Quote
Old 28-11-2017, 09:18 AM   #2
Senior Member
 
Join Date: Sep 2017
Posts: 1,479
http://www.businesstimes.com.sg/comp...pital-openings
IHH Q3 net profit plunges on higher costs from new hospital openings
Mon, Nov 27, 2017 - 6:59 PM Claire Huang huangjy@sph.com.sg

MAINBOARD-LISTED IHH Healthcare Berhad's third-quarter net profit plunged on the back of higher costs from depreciation and amortisation, as well as finance costs led by the opening of Gleneagles Hong Kong Hospital and Acibadem Altunizade Hospital.
In a filing to the bourse operator on Monday, the healthcare provider said net profit for the three months as at end-September fell 53 per cent year-on-year to RM82.1 million (S$27 million), dented by the expected start-up costs arising from the opening of the new hospitals. Excluding the exceptional items, net profit dropped 42 per cent to RM125.4 million.
Revenue for the quarter rose 15 per cent year-on-year to RM2.8 billion, driven by sustained growth in inpatient admissions and revenue intensity across most home markets, as well as the ramp-up of new hospitals opened in March 2017.
IHH said Tokuda Group and City Clinic Group in Bulgaria, acquired in June 2016 and since consolidated into Acibadem, also contributed to the higher revenue.
Earnings before interest, tax, depreciation, amortisation, exchange differences and other non-operational items (Ebitda) grew 3 per cent to RM562.4 million in Q3. This, as sustained operational growth in core markets offset the impact from the start-up costs incurred by the newly opened hospitals, as well as from the higher operating and staff costs, the group said.
For the first nine months of the year, net profit jumped 33 per cent to RM868.7 million while net profit excluding exceptional items grew 36 per cent to RM413.4 million.
Revenue for the nine months went up 12 per cent year-on-year to RM8.3 billion, while Ebitda dipped 3 per cent to RM1.7 billion.
As at end-September, IHH recorded a cash balance of RM5.8 billion, indicating a healthy financial position. Net gearing stood at 0.05 times compared with 0.21 times in the year-ago period.
Said IHH managing director and chief executive Tan See Leng: "We continue to deliver topline and Ebitda growth, underlining the inherent strength of our differentiated strategy. While the start-up costs for Gleneagles Hong Kong and Acibadem Altunizade have had a short-term impact on our earnings, these were according to our plans and within expectations, creating the momentum to take us to the next level on full ramp-up next year."
He noted that the group is now well-placed to expand in Greater China as its next home market.
"We also continue to build out our cutting-edge capabilities, and now have the distinction of being the region's only private healthcare provider with in-house molecular diagnostics capabilities to customise medical treatment after acquiring Angsana Holdings," added Dr Tan.
In its outlook, IHH said it expects cost pressures in terms of wage inflation, higher purchasing costs with a stronger US dollar, higher pre-operating costs and start-up costs from new operations that would partially erode profitability in the initial stages.
To mitigate these effects, IHH said it would remain prudent in its cost management, "undertake ways to improve the mix of higher revenue intensity cases and ramp up new facilities to achieve optimal operating efficiencies".
The stock closed down four cents to S$1.83 on Monday, before results were out.
Separately, the group said its executive chairman, Abu Bakar Suleiman, will retire from his role as president of IMU Health on Dec 31 and assume an advisory role from next year. "Presently, Dr Abu Bakar is the chairman of IMU Health and will continue as such," IHH said.
The group's current non-executive deputy chairman, Mohammed Azlan Hashim, will be redesignated as non-executive chairman from Jan 1.

Price link: http://www.shareinvestor.com/fundame...counter=Q0F.SI
Jupiter2017 is offline   Reply With Quote
Old 28-11-2017, 01:32 PM   #3
Senior Member
 
Join Date: Sep 2017
Posts: 1,479
http://www.businesstimes.com.sg/comp...thcare-ratings
Brokers' take: Analysts cut target prices but maintain IHH Healthcare ratings
Tue, Nov 28, 2017 - 11:13 AM Rachel Mui rachmui@sph.com.sg

ANALYSTS from CIMB and UOB Kay Hian have reduced their target prices for IHH Healthcare as the firm's third-quarter earnings came in below estimates, with startup losses associated with expansion still the main earnings drag.
CIMB reduced its target price to RM6.36 per share from RM6.99 and kept its "add" rating on the stock, while UOB Kay Hian reduced its target price to S$1.71, down from S$1.73, and maintained its "hold" rating.
As at 10.46am on Tuesday, IHH Healthcare was trading 1.09 per cent lower at S$1.81 apiece.
CIMB noted that the firm's earnings before interest, taxes, depreciation and amortisation (Ebita) was largely eroded by the RM69 million (S$22.6 million) startup costs from Gleneagles HK (GHK), which resulted in a 42.4 per cent drop in core net profit. This figure formed only 47 per cent of their consensus estimates. Similarly, UOB Kay Hian noted that year on year (y-o-y), costs remained high for the firm due to higher depreciation, finance costs and staff costs.
However, IHH continues to record a "double-digit y-o-y improvement in average revenue per inpatient admission for both its Singapore and Malaysia operations, thanks to its strong appeal to foreign patients particularly from Indonesia and Indo-China", CIMB said.
Likewise, UOB added that Singapore and Malaysia have performed well on high intensity cases, with IHH recording a 25 per cent y-o-y increase in revenue from Indonesian patients for the third quarter this year. In Malaysia, the firm's nine-month 2017 revenue also rose by 11.1 per cent from the preceding year.
"This was largely due to the ramp-up of centres of excellence, improvement of clinical outcomes as well as upgrade of equipment and facilities at the hospitals," UOB said.
While GHK, which opened in March this year, is still loss making, CIMB said that its Ebita loss narrowed for the third quarter this year. Therefore, the broker "remains positive on its continual ramp-up in operations (especially more complex procedures) and month-on-month growth in patient load". It expects GHK to reach Ebita breakeven in fiscal 2019.
Looking ahead, IHH remains on track in its China expansion plans, starting with Chengdu, Nanjing and Shanghai in late 2018 to 2020.
"Its 350-bed capacity Chengdu hospital will first open with 80-100 beds and an estimated 40-50 doctors. We expect some pre-opening expenses from H2 FY18 onwards, but do not think that this will be extensive given the 'asset-light' model and 49 per cent ownership," CIMB said.
It added that the firm's recent issuance of US$500 million perpetual bonds is a "sizeable war chest for the group to pursue more aggressive M&As in the near-term". Although potential M&As (mergers and acquisitions) are a key catalyst, CIMB said that downside risk could stem from poor overseas execution.
Similarly, while UOB noted that IHH's near-term earnings may be negatively affected by expansion plans, it remains positive on the long-term prospects of the firm because of growth in China, Hong Kong and India.
Jupiter2017 is offline   Reply With Quote
Old 01-12-2017, 11:36 AM   #4
Supremacy Member
 
Wood41's Avatar
 
Join Date: Jan 2002
Posts: 8,624
Like RMG, the recent buyers would be in deep regret.
Malaysia govt funds were buying last 1-2 years.
Wood41 is offline   Reply With Quote
Old 02-05-2018, 08:50 PM   #5
High Honorary Member
 
mrclubbie's Avatar
 
Join Date: Oct 2008
Posts: 170,343
IHH sweetens offer for India's Fortis in heated bidding war

IHH sweetens offer for India's Fortis in heated bidding war

https://www.straitstimes.com/busines...ed-bidding-war



SINGAPORE - Asia's largest private healthcare operator IHH Healthcare has revised its bid for cash-strapped Fortis Healthcare, which runs about 30 hospitals in India. This deal sweetener comes amid a heated bidding war with four other entities looking to secure a stake in India's second-largest hospital chain.

In its filing with the Singapore bourse on Wednesday (May 2), IHH Healthcare said its proposal for an immediate equity infusion of 650 crore rupees (S$130 million) will now be priced at 175 rupees per share, a 9.4 per cent premium from the 160 rupees apiece proposed in April.

A subsequent round of equity infusion for up to 3,350 crore rupees will also be at a share price not exceeding 175 rupees. However, this subsequent equity infusion will be subject to due diligence, and the "execution of mutually acceptable binding definitive documents", IHH Healthcare said.

The other parties vying for a piece of Fortis include TPG backed-Manipal Hospital, the Munjal and Burman families, China's Fosun International and KKR-backed Radiant Life Care.

Tuesday was the deadline for the binding offers, which will be evaluated by an expert advisory committee. Fortis' board is due to meet on May 10 to review the committee's recommendations.

In addition, IHH Healthcare noted that the revised terms of its proposal shall stand withdrawn if the company does not hear from Fortis by May 15.

As at 3.35pm on Wednesday, shares in IHH Healthcare were trading down 1.47 per cent, or three Singapore cents, to S$2.01 apiece.
__________________
Hitori
Hitokoto
Hitorigoto
mrclubbie is offline   Reply With Quote
Old 25-05-2018, 05:19 PM   #6
High Honorary Member
 
mrclubbie's Avatar
 
Join Date: Oct 2008
Posts: 170,343
http://infopub.sgx.com/FileOpen/IHH_...&FileID=507409
__________________
Hitori
Hitokoto
Hitorigoto
mrclubbie is offline   Reply With Quote
Old 03-07-2018, 08:11 PM   #7
High Honorary Member
 
mrclubbie's Avatar
 
Join Date: Oct 2008
Posts: 170,343
IHH Healthcare sees revenue growth from two new China hospitals

IHH Healthcare sees revenue growth from two new China hospitals

https://sbr.com.sg/source/motley-foo...hina-hospitals

It will also expand its hospitals in Malaysia and Turkey.

With a market capitalisation of S$16.6 billion, IHH Healthcare Bhd (SGX:Q0F) is — by far — the largest healthcare stock listed in Singapore. The group operates 49 hospitals and 30 medical centres around the world, including prominent private hospitals in Singapore, namely Gleneagles, Mount Elizabeth and Parkway.

IHH Healthcare has also initiated a few more projects that are due for completion by 2019.

The phase 2 expansion of Pantai Hospital in Kuala Lumpur, and the expansion of Acibadem Maslak in Turkey will increase the bed capacity of the hospitals by 120 beds and 195 beds, respectively. On top of that, the 350-bed Gleneagles Chengdu is slated to be opened this year. Gleaneagles Shanghai, which has a 450-bed capacity, is also expected to be completed in 2019.

These four projects, especially the two new hospital openings in China, is likely drive revenue growth.

There might be initial teething issues, and high start-up costs, but the long-term impact from these openings will likely be positive for the group’s bottom line.

In its most recent quarter, the group had a mixed performance.

On one hand, the company’s revenue and EBITDA (earnings before interest tax depreciation and amortisation) were up from a year ago, benefiting from the contribution of two newly opened hospitals, and organic growth from its existing hospitals.

On the other hand, the group’s net profit (after tax) for the quarter plunged 40% after excluding one-off gains seen last year. Teething issues, coupled with higher operating, and depreciation cost were the main culprits behind the decline.

However, despite the lower bottom line figures, there are still reasons to be optimistic for the group. Here are three growth drivers that can improve the company’s margins and profit in the future.

Full-year contribution from new hospitals

IHH Healthcare has a vast a network of hospitals, medical centres and clinics, but it has no intention to rest on its laurels. The company is aggressively re-investing its cashflow into new projects, which include the expansion of its existing hospitals and the development of new hospitals.

As mentioned earlier, the group opened two new hospitals in March 2017, namely Gleneagles Hong Kong, and Acibadem Altunizade in Turkey. The former represents its first foray into China. The full year revenue contribution from both hospitals will happen this year.

As the two hospitals mature, their contribution to the bottom line should be more prominent as the hospitals gains traction, and the initial one-off operating expenses fade away.

Organic growth

IHH Healthcare’s portfolio of healthcare facilities are also generating more revenue over time. In its most recent quarter, average revenue per inpatient admission grew at most of its hospitals.

On top of that, inpatient volume also increased in all geographies except for Malaysia. As the population ages and middle class population grows, healthcare expenditure expected to increase over the next few years. The trends could provide a tailwind for the company’s organic growth for many years to come.

The Foolish bottom line

With the opening of new hospitals, there is bound to be short-term teething issues that will eat into margins. Hence, the lower profit we see in IHH’s recent earnings update.

However, investors should focus more on the long-term health of the company.

IHH Healthcare has strong cashflow from its operations, and a healthy balance sheet that should see it through any near-term start-up challenges as it expands its footprint in China. As such, I do believe, that once the new hospitals are fully up and running, the group will likely see healthy margins return together with strong bottom line growth.
__________________
Hitori
Hitokoto
Hitorigoto
mrclubbie is offline   Reply With Quote
Old 03-07-2018, 08:35 PM   #8
Arch-Supremacy Member
 
yyhwin's Avatar
 
Join Date: Jul 2006
Posts: 22,307
IHH just bid for Fortis and indirectly also plan to buy out assets for RHT, very aggressive.
lbs likes this.
yyhwin is online now   Reply With Quote
Old 04-07-2018, 06:45 AM   #9
Supremacy Member
 
Join Date: Jan 2018
Posts: 5,678
IHH share price, like most Malaysia ‘blue chips’ , always get artificially supported by those EPF like Malaysia institutions.

KLSE market has few retail & foreign investors.
Mergui219067 is offline   Reply With Quote
Old 13-08-2018, 05:19 PM   #10
Supremacy Member
 
Join Date: Jan 2018
Posts: 5,678
IHH heavy in Turkey ?
Lira becomes lah lah lah ..
Mergui219067 is offline   Reply With Quote
Old 02-04-2019, 08:15 PM   #11
High Honorary Member
 
mrclubbie's Avatar
 
Join Date: Oct 2008
Posts: 170,343
KPMG struggles to spot regulatory breaches at IHH Healthcare Berhad

KPMG struggles to spot regulatory breaches at IHH Healthcare Berhad

https://sbr.com.sg/healthcare/news/k...lthcare-berhad

A previous probe about the firm saw inter-corporate deposits and ties with Fortis’ former major shareholders.

IHH Healthcare Berhad revealed that its company's external auditors, KPMG, have said that they cannot determine if there are any regulatory non-compliances and additional adjustments or disclosures which may be needed for the audit report, as a result of further findings from ongoing investigations at Fortis Healthcare, according to a filing with the Singapore Exchange (SGX).

IHH Healthcare acquired Fortis Healthcare and its subsidiaries in November 2018. Prior to the acquisition, an investigation report by an independent external legal firm was submitted to the former Fortis board, relating to systematic lapse and override of internal controls.

Significant findings, amongst others, highlighted the placement of inter-corporate deposits and existence of possible related parties connected with former controlling shareholders of Fortis. KPMG said these may require "appropriate reassessment" by Fortis Group on the claims from, or transactions with, such parties.

In addition, it revealed that there are ongoing investigations by the Securities and Exchange Board of India (SEBI) and the Serious Fraud Investigation Office, Ministry of Corporate Affairs of India. In October 2018, SEBI issued interim orders which said that certain transactions were structured by some entities which appeared fictitious and fraudulent in nature, resulting in diversion of funds by former controlling shareholders of Fortis.

KPMG said in its independent auditors' report that due to the ongoing process of the various inquiries/investigations, the external auditors of Fortis are unable to determine if there are any regulatory non-compliances and additional adjustments or disclosures which may be necessary as a result of further findings of the ongoing or future regulatory/internal investigations and the consequential impact, if any, on the consolidated financial statements of Fortis.

"Any consequential adjustments may be recorded either as adjustments to the assets acquired, and liabilities assumed in the acquisition which will have an impact on the provisional goodwill recognised by the group on acquisition of Fortis under the purchase price allocation exercise, or as post-acquisition adjustments to be recognised in the financial statements of the group in the period the adjustments are known."

That being said, KPMG highlighted that the accompanying financial statements give a true and fair view of the financial position of the group and of the company as at 31 December 2018, and of their financial performances and their cash flows for the year.

With respect to the findings by the external legal firm, the Fortis Board has implemented specific improvement projects to strengthen the process and control environment, including review and revision of operational and financial authority levels, greater oversight by Fortis Board, review and improve financial reporting processes, more robust secretarial documentation in regard to compliance to regulatory requirements and improving systems design and control enhancement.

According to KPMG’s report, Fortis Board continues to evaluate other areas to strengthen processes and build a robust governance framework, and has initiated an enquiry of the management of certain entities in the Fortis Group that were impacted in respect of the matters investigated by the external legal firm.

Following SEBI’s interim orders, Fortis Group has also taken steps to recover dues from the former controlling shareholders of Fortis and various other entities. These include initiating civil actions against the entities demanding recovery of the outstanding amounts together with interest and to secure repayment of the outstanding amounts on the assets of these entities.
__________________
Hitori
Hitokoto
Hitorigoto
mrclubbie is offline   Reply With Quote
Old 27-03-2020, 08:27 PM   #12
High Honorary Member
 
mrclubbie's Avatar
 
Join Date: Oct 2008
Posts: 170,343
IHH Healthcare auditor issues qualified opinion

IHH Healthcare auditor issues qualified opinion

https://www.straitstimes.com/busines...fied-opinion-0

SINGAPORE (THE BUSINESS TIMES) - The external auditor for IHH Healthcare has issued a qualified opinion as ongoing probes relating to the Fortis Healthcare acquisition may have an impact on adjustments to be recorded in IHH's financial statements.

KPMG said that except for the Fortis deal, IHH's latest full-year financial statements give a "true and fair" view of the financial position of the group as at Dec 31, 2019.

There was a similar qualified opinion in IHH's 2018 audited financial statements, said the Kuala Lumpur-based hospital operator.

IHH completed the acquisition of Indian hospital chain Fortis Healthcare and its units on Nov 13, 2018.

Before the deal, an investigation by an independent legal firm for the former Fortis board indicated systematic lapses and/or override of internal controls.

The Fortis group had also initiated enquiries of the management of entities within the group.

There are also investigations by the Securities and Exchange Board of India and the Serious Fraud Investigation Office under India's Corporate Affairs Ministry.

Due to the ongoing inquiries - including the need for any additional investigations by Fortis - Fortis's external auditors are unable to determine if there are any regulatory non-compliances and if any additional adjustments or disclosures may be required as a result of further findings of the investigations.

IHH posted a 15 per cent drop in net profit excluding exceptional items for the fourth quarter last year, as new loans were taken for the Fortis acquisition and for working capital while a unit's euro bank loans and interest were swapped into the appreciating Turkish lira.

IHH shares closed 4.14 per cent higher at $1.76 yesterday.
__________________
Hitori
Hitokoto
Hitorigoto
mrclubbie is offline   Reply With Quote
Old 14-05-2020, 11:02 AM   #13
High Honorary Member
 
mrclubbie's Avatar
 
Join Date: Oct 2008
Posts: 170,343
IHH Healthcare rolls out telemedicine services

IHH Healthcare rolls out telemedicine services

https://sbr.com.sg/healthcare/more-n...icine-services

The expansion aims to meet the evolving needs of patients.

IHH Healthcare has made virtual consultation services available across all its key markets Malaysia, Singapore, Turkey, India and Hong Kong, according to an announcement.

The set of services include online consultation to doorstep drug delivery, along with the option for a transfer to the group’s facilities, if necessary.

Patients can book virtual consultations with doctors from all 15 Pantai and Gleneagles hospitals in Malaysia, Parkway Shenton clinics in Singapore, 21 Acibadem hospitals in Turkey, Bulgaria, Macedonia and Netherlands, Gleneagles hospital in Hong Kong, as well as 23 Fortis hospitals, 5 Gleneagles Global hospitals and Continental Hospital in India.

Earlier this March, IHH invested in regional telehealth platform Doctor Anywhere and in Lucence Diagnostics, which offers blood-based screening and treatment monitoring solutions for oncology patients.
__________________
Hitori
Hitokoto
Hitorigoto
mrclubbie is offline   Reply With Quote
Reply
Important Forum Advisory Note
This forum is moderated by volunteer moderators who will react only to members' feedback on posts. Moderators are not employees or representatives of HWZ. Forum members and moderators are responsible for their own posts.

Please refer to our Terms of Service for more information.


Thread Tools

Posting Rules

Smilies are On
[IMG] code is On
HTML code is Off
Trackbacks are Off
Pingbacks are Off
Refbacks are On